Supplementary Documents [IFRS]

Financial results for the fiscal year 2016 (FY2016)

Astellas Pharma Inc.

- FY2016 Financial Results
  - For the year ended March 31, 2017
  - Three months ended March 31, 2017
- Pipeline list

Cautionary Notes

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

[For the year ended March 31, 2017]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY15 Full Year	FY16 Full Year	Change	Change (%)
Sales	1,372.7	1,311.7	-61.0	-4.4%
Cost of sales	335.6	320.5	-15.1	-4.5%
Ratio to Sales	24.4%	24.4%		
Gross profit	1,037.1	991.2	-45.9	-4.4%
SG&A expenses	500.4	470.8	-29.6	-5.9%
Ratio to Sales	36.5%	35.9%		
Advertising and Sales Promotion	169.1	144.1	-25.1	-14.8%
Personnel expenses	186.1	177.0	-9.1	-4.9%
Other	145.1	149.7	4.6	3.2%
R&D expenses	225.7	208.1	-17.5	-7.8%
Ratio to Sales	16.4%	15.9%		
Amortisation of intangible assets	42.4	35.8	-6.5	-15.5%
Share of profits/losses of associates and joint ventures	-1.2	-1.9	-0.6	-
Other income	1.7	9.6	7.9	467.9%
Net foreign exchange gains	-	6.9	6.9	-
Other expense	20.2	23.3	3.2	15.7%
Impairment losses	9.5	18.1	8.5	89.8%
Net foreign exchange losses	7.0	-	-7.0	-
Operating profit	249.0	260.8	11.8	4.8%
Ratio to Sales	18.1%	19.9%		
Finance income	14.4	22.9	8.5	59.0%
Gain on sales of available-for-sale financial assets	12.3	21.3	9.0	73.2%
Finance expense	1.6	2.0	0.3	21.5%
Impairment losses for available-for-sale financial assets	0.4	0.6	0.3	73.6%
Profit before tax	261.8	281.8	20.0	7.6%
Ratio to Sales	19.1%	21.5%		
Income tax expense	68.1	63.1	-5.0	-7.4%
Profit for the year	193.7	218.7	25.0	12.9%
Ratio to Sales	14.1%	16.7%		
Comprehensive income	130.9	174.6	43.8	33.4%

Unit: B¥

	FY16 Revised Forecasts	Forecasts FY17 Full Year	Change from FY16 Change (%)
Sales	1,300.0	1,279.0	-2.5%
Cost of sales			
Ratio to Sales			
Gross profit			
SG&A expenses			
Ratio to Sales			
Advertising and Sales Promotion			
Personnel expenses			
Other			
R&D expenses	216.0	218.0	4.7%
Ratio to Sales	16.6%	17.0%	
Amortisation of intangible assets			
Share of profits/losses of associates and joint ventures			
Other income			
Net foreign exchange gains			
Other expense			
Impairment losses			
Net foreign exchange losses			
Operating profit	267.0	254.0	-2.6%
Ratio to Sales	20.5%	19.9%	
Finance income			
Gain on sales of available-for-sale financial assets			
Finance expense			
Impairment losses for available-for-sale financial assets			
Profit before tax	268.0	260.0	-7.7%
Ratio to Sales	20.6%	20.3%	
Income tax expense			
Profit for the year	198.0	198.0	-9.5%
Ratio to Sales	15.2%	15.5%	

2. Consolidated Results (Core Basis)

Unit: B¥

	FY15 Full Year	FY16 Full Year	Change	Change (%)	Unit: B¥ FY16 Revised Forecasts	Forecasts FY17 Full Year	Change from FY16 (%)
Sales	1,372.7	1,311.7	-61.0	-4.4%	1,300.0	1,279.0	-2.5%
Cost of sales	335.6	320.5	-15.1	-4.5%			
Ratio to Sales	24.4%	24.4%					
Gross profit	1,037.1	991.2	-45.9	-4.4%			
SG&A expenses	500.4	470.8	-29.6	-5.9%			
Ratio to Sales	36.5%	35.9%					
Advertising and Sales Promotion	169.1	144.1	-25.1	-14.8%			
Personnel expenses	186.1	177.0	-9.1	-4.9%			
Other	145.1	149.7	4.6	3.2%			
R&D expenses	225.7	208.1	-17.5	-7.8%	216.0	218.0	4.7%
Ratio to Sales	16.4%	15.9%			16.6%	17.0%	
Amortisation of intangible assets	42.4	35.8	-6.5	-15.5%			
Share of profits/losses of associates and joint ventures	-1.2	-1.9	-0.6	-			
Operating profit	267.5	274.6	7.1	2.7%	274.0	254.0	-7.5%
Ratio to Sales	19.5%	20.9%			21.1%	19.9%	
Finance income	2.1	1.7	-0.5	-22.6%			
Finance expense	1.0	1.3	0.3	28.0%			
Profit before Tax	268.6	274.9	6.3	2.4%			
Ratio to Sales	19.6%	21.0%					
Income tax expense	69.8	61.6	-8.2	-11.8%			
Profit for the year	198.8	213.3	14.5	7.3%	202.0	195.0	-8.6%
Ratio to Sales	14.5%	16.3%			15.5%	15.2%	

3. Exchange Rate

Unit: yen

	FY15 Ave.	FY16 Ave.	FY15 End	FY16 End	Unit: yen FY16 Revised Forecasts	Forecasts FY17 Full Year
USD/Yen	120	108	113	112	103	110
EUR/Yen	133	119	128	120	117	120

* Exchange rate fluctuations had negative impact by 94.7 billion yen on sales and negative impact by 36.3 billion yen on Core operating profit in FY2016

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY15			FY16		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Sales	**1,372.7**	**-**	**1,372.7**	**1,311.7**	**-**	**1,311.7**
Cost of sales	335.6	-	335.6	320.5	-	320.5
Gross profit	**1,037.1**	**-**	**1,037.1**	**991.2**	**-**	**991.2**
SG&A expenses	500.4	-	500.4	470.8	-	470.8
R&D expenses	225.7	-	225.7	208.1	-	208.1
Amortisation of intangible assets	42.4	-	42.4	35.8	-	35.8
Share of losses of associates and joint ventures	-1.2	-	-1.2	-1.9	-	-1.9
Other income *1	1.7	-1.7	-	9.6	-9.6	-
Other expense *1	20.2	-20.2	-	23.3	-23.3	-
Operating profit	**249.0**	**18.5**	**267.5**	**260.8**	**13.7**	**274.6**
Finance income *2	14.4	-12.3	2.1	22.9	-21.3	1.7
Finance expense *2	1.6	-0.6	1.0	2.0	-0.7	1.3
Profit before tax	**261.8**	**6.8**	**268.6**	**281.8**	**-6.9**	**274.9**
Income tax expense	68.1	1.7	69.8	63.1	-1.5	61.6
Profit for the year	**193.7**	**5.1**	**198.8**	**218.7**	**-5.4**	**213.3**

*1. “Other income” and “Other expense” are excluded from Full basis results.
“Other income” and “Other expense” include gain/loss on sale and disposal of property, plant and equipment, impairment losses, loss on the restructuring, litigation costs and foreign exchange gains/losses, etc.

*2. Gain/loss on sale of available-for-sale (“AFS”) and impairment losses of AFS included in “Finance income” and “Finance expense” are excluded from Full basis results as non-core items.

5. Sales by Region

Unit: B¥

		FY15 Full Year	FY16 Full Year	Change	Change (%)	FY16 Revised Forecasts	FY17 Full Year	Change from FY16 (%)
Sales		1,372.7	1,311.7	-61.0	-4.4%	1,300.0	1,279.0	-2.5%
	Japan	497.2	480.8	-16.4	-3.3%	483.7	426.9	-11.2%
	Ratio to Sales	36.2%	36.7%			37.2%	33.4%	
	Americas	455.1	412.4	-42.7	-9.4%	409.1	430.7	4.4%
	Ratio to Sales	33.2%	31.4%			31.5%	33.7%	
	EMEA	329.3	330.8	1.5	0.5%	322.1	319.3	-3.5%
	Ratio to Sales	24.0%	25.2%			24.8%	25.0%	
	Asia and Oceania	91.1	87.7	-3.5	-3.8%	85.1	102.1	16.4%
	Ratio to Sales	6.6%	6.7%			6.5%	8.0%	

- Calculated according to locations of sellers.
- EMEA: Europe, Middle East and Africa

6. Per Share Information

	FY15 Full Year	FY16 Full Year	FY16 Revised Forecasts	FY17 Full Year
The number of shares issued (thousand)	2,221,823	2,153,823		
Treasury Shares (thousand)	96,844	88,817		
The number of shares issued after deducting Treasury Shares (thousand)	2,124,978	2,065,005		
Earnings per share (yen)	89.75	103.69	93.71	95.88
Earnings per share (yen) core base	92.12	101.15	95.60	94.43
Dividend per share (yen)	32	34	34	36
Return on Equity (%)	15.0%	17.3%		
Dividend on Earnings (%)	5.4%	5.6%		

7. Addition to Property, Plant and Equipment

Depreciation/Amortisation

Unit: B¥

		FY15 Full Year	FY16 Full Year	Change	Change (%)	FY16 Revised Forecasts	FY17 Full Year	Change from FY16 (%)
Addition to Property, Plant and Equipment								
	Consolidated	34.0	23.9	-10.1	-29.8%	26.0	25.0	4.6%
Depreciation (PP&E)								
	Consolidated	21.0	21.9	0.9	4.4%	22.0	23.0	5.2%
Amortisation (Intangible Assets) *								
	Consolidated	48.2	41.9	-6.3	-13.1%	41.0	42.0	0.2%

* Amortisation (Intangible Assets): Including amortisation of software, etc.

8. Sales of major products

1) Sales of global products

Unit: B¥

	FY15 Full Year	FY16 Full Year	Change	Change (%)
XTANDI	252.1	252.1	0.0	0.0%
US	148.4	131.7	-16.7	-11.3%
ex-US	103.7	120.4	16.7	16.1%
Japan	26.2	23.4	-2.8	-10.6%
Americas (ex-US)	4.5	7.7	3.2	71.7%
EMEA	70.7	85.3	14.6	20.7%
Asia and Oceania	2.4	4.0	1.6	66.5%
Eligard	17.6	15.9	-1.7	-9.6%
EMEA	17.4	15.7	-1.7	-9.9%
Asia and Oceania	0.2	0.2	0.0	17.8%
Vesicare	135.6	116.1	-19.6	-14.4%
Japan	26.5	25.6	-0.9	-3.3%
Americas	63.7	53.1	-10.6	-16.7%
EMEA	39.8	32.0	-7.8	-19.6%
Asia and Oceania	5.3	5.0	-0.3	-5.2%
Betanis/Myrbetriq/BETMIGA	81.7	98.8	17.1	21.0%
Japan	21.2	25.9	4.7	22.0%
Americas	45.7	55.3	9.6	21.1%
EMEA	13.4	14.1	0.7	5.6%
Asia and Oceania	1.4	3.5	2.1	144.8%
Harnal/Omnic	53.4	47.7	-5.8	-10.8%
Sales by Astellas	50.4	45.4	-5.0	-10.0%
Japan	12.7	9.2	-3.5	-27.5%
EMEA	15.4	14.1	-1.4	-8.9%
Asia and Oceania	21.5	21.1	-0.4	-2.0%
Bulk and Royalties	3.0	2.3	-0.7	-23.8%
Prograf	203.6	186.2	-17.4	-8.5%
Sales by Astellas	200.7	183.5	-17.2	-8.6%
Japan (Including Graceptor)	49.8	48.8	-0.9	-1.9%
Americas	34.6	27.3	-7.3	-21.2%
EMEA	77.9	70.1	-7.8	-10.0%
Advagraf	31.1	30.0	-1.1	-3.5%
Asia and Oceania	38.4	37.3	-1.1	-2.9%
Exports to third parties	2.8	2.6	-0.2	-7.6%
Funguard/MYCAMINE	41.6	40.3	-1.4	-3.3%
Japan	11.7	11.2	-0.4	-3.7%
Americas	13.0	12.2	-0.8	-6.3%
EMEA	11.2	10.8	-0.4	-3.6%
Asia and Oceania	5.7	6.0	0.3	4.8%

Unit: B¥

	FY16 Revised Forecasts	Forecasts FY17 Full Year	Change from FY16 Change (%)
XTANDI	265.7	277.7	10.2%
US	143.7	133.3	1.3%
ex-US	122.0	144.4	19.9%
Japan	24.3	25.8	10.1%
Americas (ex-US)	7.2	10.1	30.7%
EMEA	86.8	101.5	19.0%
Asia and Oceania	3.7	7.0	75.9%
Eligard	15.3	17.6	10.7%
EMEA	15.0	17.2	9.6%
Asia and Oceania	0.3	0.4	83.6%
Vesicare	114.9	114.6	-1.3%
Japan	26.1	24.5	-4.4%
Americas	51.0	52.5	-1.0%
EMEA	32.5	31.4	-2.2%
Asia and Oceania	5.1	5.8	15.9%
Betanis/Myrbetriq/BETMIGA	95.1	122.8	24.2%
Japan	26.9	31.9	23.2%
Americas	50.6	68.0	23.0%
EMEA	14.5	17.7	25.0%
Asia and Oceania	3.1	5.2	47.3%
Harnal/Omnic	44.1	47.1	-1.3%
Sales by Astellas	42.1	45.2	-0.4%
Japan	9.0	6.9	-24.8%
EMEA	13.2	14.9	6.0%
Asia and Oceania	19.9	23.4	10.9%
Bulk and Royalties	1.9	1.8	-19.7%
Prograf	182.9	186.7	0.3%
Sales by Astellas	180.5	184.8	0.7%
Japan (Including Graceptor)	48.4	48.5	-0.7%
Americas	26.6	28.1	3.0%
EMEA	68.7	68.7	-2.0%
Advagraf			
Asia and Oceania	36.8	39.6	6.0%
Exports to third parties	2.4	1.9	-29.1%
Funguard/MYCAMINE	38.2	36.1	-10.4%
Japan	11.0	11.3	0.3%
Americas	11.1	9.6	-21.1%
EMEA	10.3	8.4	-22.6%
Asia and Oceania	5.8	6.8	13.5%

- Sales of products in Japan are shown in a gross sales basis.
- EMEA: Europe, Middle East and Africa

2) Sales of products in Japan

Unit: B¥

<Global products>	FY15 Full Year	FY16 Full Year	Change	Change (%)	Unit: B¥ FY16 Revised Forecasts	Forecasts FY17 Full Year	Change from FY16 Change (%)
XTANDI	26.2	23.4	-2.8	-10.6%	24.3	25.8	10.1%
Vesicare	26.5	25.6	-0.9	-3.3%	26.1	24.5	-4.4%
Betanis	21.2	25.9	4.7	22.0%	26.9	31.9	23.2%
Harnal	12.7	9.2	-3.5	-27.5%	9.0	6.9	-24.8%
Prograf （Including Graceptor）	49.8	48.8	-0.9	-1.9%	48.4	48.5	-0.7%
Funguard	11.7	11.2	-0.4	-3.7%	11.0	11.3	0.3%
<Local products in Japan>							
Micardis [Family]	97.2	93.2	-3.9	-4.1%	94.7	52.2	-44.1%
Micombi	10.1	9.4	-0.8	-7.6%			
Micamlo	26.0	26.2	0.2	0.8%			
Celecox	46.6	47.6	1.0	2.2%	48.3	48.3	1.7%
Symbicort	37.4	39.3	1.9	5.0%	40.1	41.3	5.2%
Bonoteo	14.1	13.8	-0.3	-2.2%	14.0	13.3	-3.9%
Geninax	10.8	10.1	-0.7	-6.3%	10.0	10.2	0.9%
Vaccines	41.1	34.5	-6.6	-16.1%	30.2	28.9	-16.2%
Argamate	6.2	5.8	-0.3	-5.6%	6.0	5.9	1.7%
Gonax	3.9	4.5	0.6	15.9%	4.5	4.8	7.4%
Cimzia	6.6	7.7	1.2	17.9%	8.0	9.3	20.5%
Suglat	7.3	9.5	2.2	30.2%	9.7	12.8	34.6%
Lipitor	30.9	23.2	-7.7	-24.9%	22.6	18.0	-22.1%
Myslee	17.9	14.7	-3.2	-18.0%	14.6	13.0	-11.3%
Gaster*	14.7	10.7	-4.0	-27.4%	10.7		
Seroquel	10.5	7.5	-3.0	-28.4%	7.4	5.5	-26.8%
Total Rx Sales In Japanese market	483.0	452.7	-30.3	-6.3%	453.0	391.0	-13.6%

* Entered into Asset Purchase Agreement with LTL Pharma CO., Ltd. in March 2017.

- Sales of products in Japan are shown in a gross sales basis.

3) Sales of products in Americas

Unit: B¥

	FY15 Full Year	FY16 Full Year	Change	Change (%)	Unit: B¥ FY16 Revised Forecasts	Forecasts FY17 Full Year	Change from FY16 Change (%)
Tarceva	46.8	35.2	-11.5	-24.7%			
(US)	33.8	25.8	-8.0	-23.7%			
(ex-US)	13.0	9.4	-3.5	-27.2%			
Scan* (Americas)	76.2	71.5	-4.7	-6.2%	67.7	72.3	1.1%
AmBisome (Americas)	10.9	10.5	-0.4	-3.8%	9.7	10.5	0.2%
CRESEMBA (Americas)	2.6	5.8	3.2	123.7%	5.8	8.5	46.1%

* Adenoscan + Lexiscan

4) Sales in Americas and EMEA (Local currency)

Unit: M$

Americas	FY15 Full Year	FY16 Full Year	Change	Change (%)	Unit:M$ FY16 Revised Forecasts	Forecasts FY17 Full Year	Change from FY16 Change (%)
Sales	3,788	3,805	17	0.5%	3,986	3,915	2.9%
XTANDI	1,272	1,286	14	1.1%	1,470	1,304	1.4%
US	1,235	1,215	-20	-1.6%	1,400	1,212	-0.2%
Americas (ex-US)	37	71	34	90.3%	70	92	28.7%
Tarceva	389	325	-64	-16.5%			
US	281	238	-43	-15.4%			
ex-US	108	87	-21	-19.3%			
VESIcare	530	490	-41	-7.7%	497	478	-2.5%
Myrbetriq	380	510	130	34.2%	493	618	21.2%
Prograf	288	252	-36	-12.6%	259	256	1.5%
Scan*	634	660	26	4.0%	660	657	-0.4%
MYCAMINE	109	113	4	3.9%	108	88	-22.3%
AmBisome	91	97	6	6.6%	95	96	-1.3%
CRESEMBA	22	53	32	147.9%	56	77	44.0%

* Adenoscan + Lexiscan

Unit: M€

EMEA	FY15 Full Year	FY16 Full Year	Change	Change (%)	Unit:M€ FY16 Revised Forecasts	Forecasts FY17 Full Year	Change from FY16 Change (%)
Sales	2,484	2,785	301	12.1%	2,763	2,661	-4.4%
XTANDI	533	718	185	34.7%	745	846	17.8%
Eligard	131	132	1	0.6%	129	143	8.5%
Vesicare	300	270	-31	-10.2%	279	261	-3.1%
BETMIGA	101	119	18	17.8%	125	147	23.8%
Omnic	139	138	-1	-1.0%	130	140	1.4%
Sales by Astellas	116	118	2	1.7%	114	124	4.9%
Bulk and Royalties	23	19	-3	-15.0%	17	15	-20.5%
Prograf	609	612	3	0.5%	610	588	-4.0%
Sales by Astellas	588	590	2	0.4%	590	572	-3.0%
Advagraf	234	252	18	7.7%			
Exports to third parties	21	22	1	3.1%	21	16	-29.8%
MYCAMINE	85	91	6	7.6%	88	70	-23.4%

- EMEA: Europe, Middle East and Africa

9.Consolidated statements of financial position

Unit: B¥

			31-Mar-16	31-Mar-17	
			Amount	Amount	Change
Assets			**1,799.3**	**1,820.9**	**21.6**
	Non-current assets		**901.8**	**944.2**	**42.4**
		Property, plant and equipment	201.0	191.1	-9.8
		Goodwill	153.1	175.3	22.2
		Other intangible assets	336.3	387.4	51.2
		Trade and other receivables	24.1	22.3	-1.8
		Investments in associates and joint ventures	2.4	3.0	0.6
		Deferred tax assets	80.7	90.3	9.6
		Other financial assets	89.4	61.6	-27.8
		Other non-current assets	14.8	13.2	-1.6
	Current assets		**897.5**	**876.7**	**-20.9**
		Inventories	161.7	182.5	20.8
		Trade and other receivables	327.6	309.8	-17.8
		Income tax receivable	16.4	11.0	-5.4
		Other financial assets	14.4	13.6	-0.8
		Other current assets	17.2	18.8	1.6
		Cash and cash equivalents	360.0	340.9	-19.1
		Assets held for sale	0.2	-	-0.2

- Due to the adjustments of the provisional fair value for the acquisition of Ocata Therepeutics, Inc. (The company name was changed to Astellas Institute for Regenerative Medicine in May 2016.), consolidated statement of financial position as of 31 March, 2016 was retrospectively revised. For the details, refer to Financial Results P.30

Unit: B¥

	31-Mar-16	31-Mar-17	
	Amount	Amount	Change
Equity and Liabilities	**1,799.3**	**1,820.9**	**21.6**
Equity	**1,259.2**	**1,271.8**	**12.6**
Equity attributable to owners of the parent	**1,259.2**	**1,271.8**	**12.6**
Share capital	103.0	103.0	-
Capital surplus	176.9	177.1	0.2
Treasury shares	-157.1	-138.2	18.9
Retained earnings	973.1	1,013.9	40.9
Other components of equity	163.4	116.0	-47.4
Liabilities	**540.1**	**549.1**	**9.0**
Non-current liabilities	**126.8**	**149.2**	**22.5**
Trade and other payables	1.6	0.4	-1.2
Deferred tax liabilities	-	25.3	25.3
Retirement benefit liabilities	39.8	36.6	-3.2
Provisions	7.1	4.9	-2.2
Other financial liabilities	0.7	28.4	27.7
Other non-current liabilities	77.6	53.5	-24.0
Current liabilities	**413.4**	**399.9**	**-13.5**
Trade and other payables	181.6	182.8	1.3
Income tax payable	19.3	10.9	-8.4
Provisions	89.9	96.6	6.7
Other financial liabilities	1.5	3.0	1.5
Other current liabilities	121.1	106.5	-14.6

10. Employees

Number of employees

	FY15 End	FY16 End
Total	17,217	17,202
Japan	7,056	7,029
Americas	3,062	3,016
EMEA	4,726	4,672
Asia and Oceania	2,373	2,485
Total Medical Representatives	6,000	5,750

- EMEA: Europe, Middle East and Africa

11. Shareholders

	FY15 End	FY16 End
Banks	31.3%	30.7%
Securities	3.9%	3.5%
Other companies	3.4%	3.4%
Foreign companies	48.5%	49.3%
Individuals and others	8.6%	9.1%
Treasury Stock*	4.3%	4.1%

* Treasury Stock does not include shares owned by the executive compensation BIP (Board Incentive Plan) trust.

[Three months ended March 31, 2017]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY16							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Sales	337.8	-1.7%	313.9	-8.7%	353.9	-6.4%	306.1	-0.3%
Cost of sales	71.5	-20.7%	74.7	-4.6%	104.6	2.4%	69.7	7.1%
Ratio to Sales	21.2%		23.8%		29.5%		22.8%	
Gross profit	266.3	5.0%	239.2	-9.9%	249.4	-9.7%	236.3	-2.3%
SG&A expenses	111.9	-5.7%	109.0	-10.0%	115.8	-5.8%	134.1	-2.6%
Ratio to Sales	33.1%		34.7%		32.7%		43.8%	
Advertising and Sales Promotion	35.8	-13.9%	33.4	-19.9%	35.9	-13.9%	38.9	-11.7%
Personnel expenses	43.5	-3.5%	42.0	-9.2%	44.3	-3.7%	47.3	-3.2%
Other	32.6	1.9%	33.6	1.3%	35.6	1.1%	47.9	7.1%
R&D expenses	51.0	-8.9%	48.6	-13.2%	48.6	-8.2%	59.8	-1.4%
Ratio to Sales	15.1%		15.5%		13.7%		19.6%	
Amortisation of intangible assets	9.0	-17.5%	8.7	-20.8%	9.0	-19.7%	9.1	-1.5%
Share of profits/losses of associates and joint ventures	-0.4	-	-0.3	-	-0.5	-	-0.6	-
Other income	0.2	-81.8%	0.1	-44.0%	6.7	-	3.0	413.5%
Net foreign exchange gains	-	-	-	-	4.8	-	2.7	-
Other expense	1.3	-81.7%	8.5	22.8%	7.9	32.2%	6.2	680.3%
Impairment losses	-	-	7.6	-	4.2	43.8%	6.2	-
Net foreign exchange losses	0.4	-	0.1	-97.8%	-	-	-	-
Operating profit	92.9	50.0%	64.2	-9.2%	74.2	-10.5%	29.5	-11.5%
Ratio to Sales	27.5%		20.4%		21.0%		9.7%	
Finance income	1.2	-79.8%	1.2	-84.0%	11.9	-	8.6	-
Gain on sales of available-for-sale financial assets	0.7	-88.1%	0.9	-85.8%	11.1	-	8.5	-
Finance expense	0.9	225.1%	0.8	166.0%	0.0	-93.2%	0.3	-60.3%
Impairment losses for available-for-sale financial assets	0.3	888.3%	0.1	14.2%	0.0	-36.3%	0.3	4.4%
Profit before tax	93.2	37.7%	64.6	-16.9%	86.1	3.7%	37.9	13.7%
Ratio to Sales	27.6%		20.6%		24.3%		12.4%	
Income tax expense	26.6	15.3%	16.1	-17.0%	22.4	4.5%	-2.0	-
Profit for the year	66.6	49.3%	48.5	-16.9%	63.7	3.4%	39.9	36.9%
Ratio to Sales	19.7%		15.4%		18.0%		13.0%	
Comprehensive income	-34.0	-	36.7	11.0%	168.3	172.8%	3.7	-

2. Consolidated Results (Core Basis)

Unit: B¥

	FY16							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Sales	337.8	-1.7%	313.9	-8.7%	353.9	-6.4%	306.1	-0.3%
Cost of sales	71.5	-20.7%	74.7	-4.6%	104.6	2.4%	69.7	7.1%
Ratio to Sales	21.2%		23.8%		29.5%		22.8%	
Gross profit	266.3	5.0%	239.2	-9.9%	249.4	-9.7%	236.3	-2.3%
SG&A expenses	111.9	-5.7%	109.0	-10.0%	115.8	-5.8%	134.1	-2.6%
Ratio to Sales	33.1%		34.7%		32.7%		43.8%	
Advertising and Sales Promotion	35.8	-13.9%	33.4	-19.9%	35.9	-13.9%	38.9	-11.7%
Personnel expenses	43.5	-3.5%	42.0	-9.2%	44.3	-3.7%	47.3	-3.2%
Other	32.6	1.9%	33.6	1.3%	35.6	1.1%	47.9	7.1%
R&D expenses	51.0	-8.9%	48.6	-13.2%	48.6	-8.2%	59.8	-1.4%
Ratio to Sales	15.1%		15.5%		13.7%		19.6%	
Amortisation of intangible assets	9.0	-17.5%	8.7	-20.8%	9.0	-19.7%	9.1	-1.5%
Share of profits/losses of associates and joint ventures	-0.4	-	-0.3	-	-0.5	-	-0.6	-
Operating profit	94.0	38.5%	72.5	-6.3%	75.4	-15.0%	32.7	-2.6%
Ratio to Sales	27.8%		23.1%		21.3%		10.7%	
Finance income	0.6	2.8%	0.2	-67.8%	0.8	74.6%	0.1	-85.1%
Finance expense	0.6	624.3%	0.7	213.0%	-	-	0.0	-
Profit before Tax	93.9	37.5%	72.1	-7.5%	76.2	-14.3%	32.8	-2.2%
Ratio to Sales	27.8%		23.0%		21.5%		10.7%	
Income tax expense	26.8	15.1%	18.6	-1.7%	19.5	-16.6%	-3.4	-182.3%
Profit for the year	67.1	49.1%	53.4	-9.3%	56.6	-13.5%	36.2	22.9%
Ratio to Sales	19.9%		17.0%		16.0%		11.8%	

3. Sales by Region

Unit: B¥

		FY16							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Sales		337.8	-1.7%	313.9	-8.7%	353.9	-6.4%	306.1	-0.3%
	Japan	124.2	-1.1%	113.0	-7.0%	142.9	-4.5%	100.7	0.3%
	Ratio to Sales	36.8%		36.0%		40.4%		32.9%	
	Americas	107.6	-6.3%	99.1	-16.1%	101.4	-12.4%	104.3	-2.0%
	Ratio to Sales	31.8%		31.6%		28.7%		34.1%	
	EMEA	85.3	4.4%	80.8	0.3%	86.9	-2.5%	77.9	-0.1%
	Ratio to Sales	25.3%		25.7%		24.5%		25.4%	
	Asia and Oceania	20.7	-3.8%	21.1	-11.0%	22.7	-3.9%	23.2	3.9%
	Ratio to Sales	6.1%		6.7%		6.4%		7.6%	

- Calculated according to locations of sellers.
- EMEA: Europe, Middle East and Africa

4. Addition to Property, Plant and Equipment
Depreciation/Amortisation

Unit: B¥

		FY16							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Addition to Property, Plant and Equipment									
	Consolidated	3.9	-69.2%	5.0	-12.9%	4.7	-35.2%	10.3	22.3%
Depreciation (PP&E)									
	Consolidated	5.5	9.9%	5.4	2.9%	5.4	3.3%	5.6	1.8%
Amortisation (Intangible Assets) *									
	Consolidated	10.4	-15.4%	10.2	-18.7%	10.6	-16.7%	10.7	0.4%

* Amortisation (Intangible Assets): Including amortisation of software, etc.

5. Sales of major products

1) Sales of global products

Unit: B¥

	FY16							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
XTANDI	64.2	8.7%	61.7	-2.4%	63.3	-4.8%	62.9	-0.7%
US	35.7	-1.4%	32.6	-14.8%	32.1	-16.4%	31.3	-11.9%
ex-US	28.5	24.8%	29.1	16.4%	31.2	11.2%	31.6	13.6%
Japan	6.1	-10.7%	5.7	-9.0%	6.2	-12.6%	5.4	-9.7%
Americas (ex-US)	1.8	70.0%	1.8	45.1%	1.7	48.1%	2.5	125.7%
EMEA	20.0	37.0%	20.8	22.8%	22.4	16.9%	22.2	10.8%
Asia and Oceania	0.7	62.5%	0.9	47.4%	0.9	38.4%	1.5	112.5%
Eligard	4.4	-0.1%	3.4	-21.8%	4.2	-13.6%	3.9	-1.6%
EMEA	4.4	-0.6%	3.4	-22.4%	4.1	-13.6%	3.8	-1.8%
Asia and Oceania	0.1	59.5%	0.1	27.9%	0.1	-12.8%	0.1	13.5%
Vesicare	30.4	-14.0%	29.4	-14.5%	29.5	-16.1%	26.8	-12.9%
Japan	7.0	1.7%	6.0	-6.7%	7.0	-3.8%	5.6	-4.7%
Americas	13.6	-20.5%	14.1	-13.3%	12.9	-17.9%	12.5	-14.9%
EMEA	8.7	-14.8%	7.9	-22.3%	8.2	-23.0%	7.3	-17.8%
Asia and Oceania	1.2	-3.3%	1.2	-15.7%	1.4	-3.5%	1.3	2.4%
Betanis/Myrbetriq/BETMIGA	23.6	30.1%	22.1	10.9%	25.9	17.7%	27.2	25.9%
Japan	6.4	32.5%	5.9	21.5%	7.2	19.4%	6.3	16.0%
Americas	12.9	31.4%	12.1	4.5%	13.9	16.5%	16.3	32.9%
EMEA	3.5	6.4%	3.4	0.9%	3.8	8.0%	3.5	7.0%
Asia and Oceania	0.7	606.9%	0.7	351.4%	1.0	89.7%	1.1	71.2%
Harnal/Omnic	12.1	-14.6%	11.3	-12.3%	12.2	-17.0%	12.0	3.3%
Sales by Astellas	11.5	-13.3%	11.0	-11.3%	11.8	-13.2%	11.1	-0.7%
Japan	2.6	-25.1%	2.3	-30.7%	2.5	-28.2%	1.9	-25.6%
EMEA	3.7	-22.5%	3.1	-5.4%	3.7	-13.6%	3.6	14.4%
Asia and Oceania	5.2	3.3%	5.3	-5.2%	5.4	-6.0%	5.3	0.7%
Bulk and Royalties	0.6	-34.4%	0.4	-33.1%	0.4	-64.7%	1.0	90.7%
Prograf	49.4	-1.9%	44.8	-17.4%	48.1	-9.1%	43.9	-4.7%
Sales by Astellas	48.7	-2.4%	43.9	-17.5%	47.6	-8.5%	43.3	-4.9%
Japan (Including Graceptor)	12.9	1.4%	11.9	-6.2%	13.3	-2.7%	10.7	0.3%
Americas	7.7	-8.4%	6.4	-33.8%	6.6	-25.4%	6.6	-14.1%
EMEA	19.0	-2.8%	16.6	-19.0%	17.8	-11.3%	16.6	-6.1%
Advagraf	7.9	5.1%	7.1	-14.3%	7.6	-6.4%	7.4	3.2%
Asia and Oceania	9.0	-1.3%	9.0	-12.9%	10.0	4.5%	9.4	-0.9%
Exports to third parties	0.8	45.6%	0.9	-13.7%	0.4	-46.7%	0.6	11.9%
Funguard/MYCAMINE	10.0	-2.5%	10.1	-6.5%	10.6	-2.3%	9.5	-1.8%
Japan	2.7	-7.0%	2.9	-7.0%	3.3	2.6%	2.3	-3.9%
Americas	3.1	-4.9%	2.9	-16.8%	3.1	-7.2%	3.2	5.2%
EMEA	2.8	-2.8%	2.8	1.1%	2.8	-1.0%	2.5	-11.8%
Asia and Oceania	1.5	14.9%	1.5	4.2%	1.4	-4.0%	1.6	5.7%

- Sales of products in Japan are shown in a gross sales basis.
- EMEA: Europe, Middle East and Africa

2) Sales of products in Japan

Unit: B¥

	FY16							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
<Global products>	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
XTANDI	6.1	-10.7%	5.7	-9.0%	6.2	-12.6%	5.4	-9.7%
Vesicare	7.0	1.7%	6.0	-6.7%	7.0	-3.8%	5.6	-4.7%
Betanis	6.4	32.5%	5.9	21.5%	7.2	19.4%	6.3	16.0%
Harnal	2.6	-25.1%	2.3	-30.7%	2.5	-28.2%	1.9	-25.6%
Prograf （Including Graceptor）	12.9	1.4%	11.9	-6.2%	13.3	-2.7%	10.7	0.3%
Funguard	2.7	-7.0%	2.9	-7.0%	3.3	2.6%	2.3	-3.9%
<Local products in Japan>								
Micardis [Family]	24.7	-0.4%	22.1	-6.8%	26.6	-6.5%	19.8	-1.9%
Micombi	2.5	-4.8%	2.2	-10.3%	2.6	-9.9%	2.0	-4.7%
Micamlo	6.8	5.2%	6.2	-1.2%	7.4	-2.2%	5.8	1.8%
Celecox	12.4	4.9%	11.7	1.2%	12.9	1.4%	10.5	1.1%
Symbicort	9.8	9.3%	8.8	3.6%	11.9	5.2%	8.7	1.7%
Bonoteo	3.6	-0.8%	3.3	-1.3%	3.8	-2.4%	3.0	-4.4%
Geninax	2.5	-12.5%	1.8	-9.3%	3.6	-5.2%	2.3	2.2%
Vaccines	3.8	-42.4%	7.3	-1.5%	20.5	-16.9%	2.9	17.5%
Argamate	1.5	-0.4%	1.4	-6.8%	1.5	-7.6%	1.3	-7.6%
Gonax	1.1	14.7%	1.1	10.7%	1.2	16.0%	1.1	22.5%
Cimzia	1.9	20.8%	1.9	18.4%	2.1	16.0%	1.8	16.4%
Suglat	2.3	14.9%	2.3	58.2%	2.7	33.7%	2.2	21.6%
Lipitor	6.4	-22.8%	5.7	-27.8%	6.3	-25.5%	4.7	-23.3%
Myslee	3.9	-15.8%	3.7	-19.9%	4.0	-20.1%	3.1	-15.7%
Gaster*	3.0	-24.6%	2.6	-30.5%	2.9	-28.2%	2.2	-26.0%
Seroquel	2.2	-25.3%	1.8	-32.1%	2.0	-29.3%	1.5	-26.9%
Total Rx Sales In Japanese market	114.8	-6.1%	107.0	-9.1%	136.4	-6.7%	94.6	-2.4%

* Entered into Asset Purchase Agreement with LTL Pharma CO., Ltd. in March 2017.

- Sales of products in Japan are shown in a gross sales basis.

3) Sales of products in Americas

Unit: B¥

	FY16							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Tarceva	9.4	-28.4%	8.5	-31.5%	9.8	-16.5%	7.5	-20.8%
(US)	6.8	-30.2%	6.4	-28.4%	7.2	-15.4%	5.4	-18.7%
(ex-US)	2.6	-23.3%	2.1	-39.5%	2.6	-19.5%	2.1	-25.6%
Scan* (Americas)	19.3	-7.3%	16.1	-18.8%	16.4	-9.7%	19.7	13.3%
AmBisome (Americas)	2.4	-12.9%	2.3	-14.6%	3.1	12.1%	2.7	0.3%
CRESEMBA (Americas)	1.3	346.4%	1.2	120.7%	1.6	84.0%	1.7	93.2%

* Adenoscan + Lexiscan

4) Sales in Americas and EMEA (Local currency)

Unit:M$

	FY16							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
Americas	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Sales	995	5.2%	968	0.2%	927	-2.8%	916	-0.8%
XTANDI	347	12.9%	336	3.9%	308	-5.3%	296	-6.7%
US	330	10.7%	318	1.7%	293	-7.3%	273	-11.1%
Americas (ex-US)	16	90.8%	17	72.9%	15	64.2%	23	132.8%
Tarceva	87	-19.6%	83	-18.1%	90	-7.1%	65	-21.5%
US	63	-21.6%	62	-14.5%	66	-5.8%	47	-19.7%
ex-US	24	-13.9%	21	-27.4%	24	-10.5%	18	-25.7%
VESIcare	126	-10.7%	137	3.3%	118	-9.0%	109	-14.3%
Myrbetriq	119	47.5%	119	24.7%	128	29.7%	144	36.7%
Prograf	71	2.8%	63	-20.8%	60	-17.3%	58	-13.6%
Scan*	178	4.0%	158	-2.7%	150	0.0%	174	15.2%
MYCAMINE	29	6.7%	28	-0.6%	28	3.1%	28	6.6%
AmBisome	23	-2.2%	23	1.9%	28	25.2%	24	2.0%
CRESEMBA	12	400.9%	12	162.7%	15	105.8%	15	100.4%

* Adenoscan + Lexiscan

Unit:M€

	FY16							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
EMEA	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Sales	699	14.8%	706	19.3%	738	10.2%	642	4.7%
XTANDI	164	50.6%	181	45.5%	190	32.2%	183	17.5%
Eligard	36	9.3%	30	-7.0%	35	-2.4%	31	2.7%
Vesicare	71	-6.3%	69	-7.4%	69	-13.1%	60	-14.2%
BETMIGA	29	16.9%	29	20.0%	32	22.0%	29	12.3%
Omnic	35	-16.9%	31	8.7%	34	-13.8%	38	30.1%
Sales by Astellas	30	-14.8%	28	13.2%	31	-2.4%	30	19.1%
Bulk and Royalties	5	-27.8%	3	-18.6%	3	-60.0%	8	97.8%
Prograf	162	8.2%	153	-3.2%	155	-1.4%	142	-1.3%
Sales by Astellas	156	6.8%	146	-3.4%	151	0.2%	137	-1.8%
Advagraf	65	15.6%	62	2.1%	64	5.7%	61	8.1%
Exports to third parties	6	59.8%	7	1.8%	4	-39.7%	5	15.3%
MYCAMINE	23	6.9%	24	20.0%	24	11.8%	20	-7.5%

- EMEA: Europe, Middle East and Africa

R&D Pipeline (As of April 2017)

Underlined items indicate changes from the previous announcement on January 31, 2017.

Oncology (1/2)

*Compounds with "In-house" in this column include ones discovered by collaborative research.

Code No. Generic Name	Classification	Target Disease	Phase / Area	Dosage Form	Licensor*	Remarks
MDV3100 enzalutamide	Androgen receptor inhibitor	Metastatic castration-resistant prostate cancer (Tablet)	Filed (Mar. 2016) / Europe	Oral	Pfizer	New formulation
		Castration-resistant prostate cancer (Tablet)	Filed (Sept. 2016) / Japan			New formulation
		Non-metastatic castration-resistant prostate cancer	P-III / US, Europe, Asia			New indication
		Prostate cancer in patients with non-metastatic biochemical recurrence	P-III / US, Europe, Asia			New indication
		Metastatic hormone-sensitive prostate cancer	P-III / US, Europe, Japan, Asia			New indication
		Triple-negative breast cancer	P-III / US, Europe, Japan, Asia			New indication
		Breast cancer (ER/PR positive, HER2 positive)	P-II / US, Europe			New indication
		Hepatocellular carcinoma	P-II / US, Europe, Asia			New indication
ASP2215 gilteritinib	FLT3/AXL inhibitor	Acute myeloid leukemia	P-III / US, Europe, Japan, Asia	Oral	In-house	
ASP8273 naquotinib	Mutant-selective irreversible EGFR inhibitor	Non-small cell lung cancer	P-III / US, Europe, Japan, Asia	Oral	In-house	
ASP3550 degarelix	GnRH antagonist	Prostate cancer (3-month formulation)	P-III / Japan	Injection	Ferring	New formulation
AGS-16C3F	ADC targeting ENPP3	Renal cell carcinoma	P-II / US, Europe	Injection	In-house (ADC technology in-licensed from Seattle Genetics)	
IMAB362	Anti-Claudin 18.2 monoclonal antibody	Gastroesophageal adenocarcinoma	P-II / Europe	Injection	In-house (Ganymed)	
ASG-22ME enfortumab vedotin	ADC targeting nectin-4	Urothelial cancer	P-II / US P-I / Japan	Injection	In-house (co-development with Seattle Genetics)	
AMG 103 blinatumomab	Anti-CD19 BiTE antibody	Acute lymphoblastic leukemia	P-II / Japan	Injection	Amgen (co-development with Amgen Astellas)	

Oncology (2/2)

*Compounds with "In-house" in this column include ones discovered by collaborative research.

Code No. Generic Name	Classification	Target Disease	Phase / Area	Dosage Form	Licensor*	Remarks
ASG-15ME		Urothelial cancer	P-I	Injection	In-house (co-development with Seattle Genetics)	
ASP5878		Cancer	P-I	Oral	In-house	
ASP4132		Cancer	P-I	Oral	In-house	
AGS67E		Lymphoid malignancies	P-I	Injection	In-house (ADC technology in-licensed from Seattle Genetics)	
AGS62P1		Acute myeloid leukemia	P-I	Injection	In-house (ADC technology, EuCODE license from Ambrx)	

Update from the previous announcement (Jan. 2017):

ASG-22ME (enfortumab vedotin): Clinical development for urothelial cancer has been initiated in Japan.

Urology and Nephrology

*Compounds with "In-house" in this column include ones discovered by collaborative research.

Code No. Generic Name	Classification	Target Disease	Phase / Area	Dosage Form	Licensor*	Remarks
YM905 solifenacin	Muscarine M_3 receptor antagonist	Neurogenic detrusor overactivity in pediatric patients	Filed (Feb. 2017) / US Filed (Apr. 2017) / Europe	Oral	In-house	New indication (pediatric)
EB178 solifenacin/ mirabegron	Concomitant use of solifenacin and mirabegron	Urinary frequency, urinary incontinence or urgency associated with overactive bladder	P-III / US, Europe, Asia	Oral	In-house	
ASP1517 (FG-4592) roxadustat	HIF stabilizer	Anemia associated with chronic kidney disease in patients not on dialysis and on dialysis	P-III / Europe P-III / Japan	Oral	FibroGen	
YM178 mirabegron	Beta 3 receptor agonist	Neurogenic detrusor overactivity in pediatric patients	P-III / Europe	Oral	In-house	New indication (pediatric)
YM311 (FG-2216)	HIF stabilizer	Renal anemia	P-II / Europe P-I / Japan	Oral	FibroGen	
ASP8232	VAP-1 inhibitor	Diabetic nephropathy	P-II / Europe	Oral	In-house	
ASP6294	Nerve Growth Factor (NGF) neutralization antibody	Bladder pain syndrome / Interstitial cystitis	P-II / Europe	Injection	In-house	
ASP6282		Underactive bladder	P-I	Oral	In-house	
ASP7398		Nocturia	P-I	Oral	In-house	
ASP8302		Underactive bladder	P-I	Oral	In-house	
ASP7713		Underactive bladder	P-I	Oral	In-house	

Update from the previous announcement (Jan. 2017):
YM905 (solifenacin): Filed for neurogenic detrusor overactivity in pediatric patients in US and Europe.
ASP6294: Clinical development for bladder pain syndrome/interstitial cystitis has been progressed from Phase 1 to Phase 2.
ASP7713: Clinical development for underactive bladder has been initiated.

Immunology and Neuroscience

*Compounds with "In-house" in this column include ones discovered by collaborative research.

Code No. Generic Name	Classification	Target Disease	Phase / Area	Dosage Form	Licensor*	Remarks
FK949E quetiapine	Serotonin / dopamine antagonist	Improvement of depressive symptoms associated with bipolar disorder (Extended-release tablet)	Filed (Aug. 2016) / Japan	Oral	AstraZeneca	
ASP0113 (VCL-CB01)	DNA vaccine for cytomegalovirus	Cytomegalovirus reactivation in hematopoietic cell transplant recipients	P-III / US, Europe, Japan	Injection	Vical	
ASP015K peficitinib	JAK inhibitor	Rheumatoid arthritis	P-III / Japan, Asia P-II / US, Europe	Oral	In-house	
ASKP1240 bleselumab	Anti-CD40 monoclonal antibody	Recurrence of focal segmental glomerulosclerosis in de novo kidney transplant recipients	P-II / US	Injection	Kyowa Hakko Kirin	
ASP1707	GnRH antagonist	Rheumatoid arthritis	P-II / Japan	Oral	In-house	
ASP7962	TrkA inhibitor	Osteoarthritis	P-II / Europe	Oral	In-house	
ASP8062	$GABA_B$ receptor positive allosteric modulator	Fibromyalgia	P-II / US	Oral	In-house	
ASP0819	$Calcium^{2+}$-activated K^+ channel opener	Fibromyalgia	P-II / US	Oral	In-house	
ASP3662	11beta-HSD1 inhibitor	Agitation associated with Alzheimer's disease	P-II / US	Oral	In-house	
ASP4070 (JRC2-LAMP-vax)	DNA vaccine for Japanese red cedar	Pollinosis caused by Japanese red cedar	P-II / Japan	Injection	Immunomic Therapeutics	
ASP5094		Rheumatoid arthritis	P-I	Injection	In-house	
ASP4345		Cognitive impairment associated with schizophrenia	P-I	Oral	In-house	
ASP7266		Severe asthma	P-I	Injection	In-house	
ASP0892		Peanut allergy	P-I	Injection	Immunomic Therapeutics	
ASP1807 (CC8464)		Neuropathic pain	P-I	Oral	Chromocell	

Update from the previous announcement (Jan. 2017):
ASP4070 (JRC2-LAMP-vax): Clinical development for pollinosis caused by Japanese red cedar has been progressed from Phase 1 to Phase 2.

Others

*Compounds with "In-house" in this column include ones discovered by collaborative research.

Code No. Generic Name	Classification	Target Disease	Phase / Area	Dosage Form	Licensor*	Remarks
AMG 785 romosozumab	Anti-Sclerostin monoclonal antibody	Osteoporosis for those at high risk of fracture	Filed (Dec. 2016) / Japan	Injection	Amgen (co-development with Amgen Astellas)	
fidaxomicin	Macrocyclic antibiotic	Infectious enteritis (bacterial target: *Clostridium difficile*)	P-III / Japan	Oral	Merck	
		Clostridium difficile infection in pediatric patients	P-III / Europe			New indication (pediatric)
ipragliflozin/ sitagliptin	Fixed dose combination of ipragliflozin and sitagliptin	Type 2 diabetes mellitus	P-III / Japan	Oral	In-house (co-development with MSD and Kotobuki)	
ASP1941 ipragliflozin	SGLT2 inhibitor	Type 1 diabetes mellitus	P-III / Japan	Oral	In-house (co-development with Kotobuki)	New indication
ASP0456 linaclotide	Guanylate cyclase-C receptor agonist	Chronic constipation	P-III / Japan	Oral	Ironwood	New indication
ASP1707	GnRH antagonist	Endometriosis	P-II / Europe, Japan	Oral	In-house	
CK-2127107	Fast skeletal troponin activator	Spinal muscular atrophy	P-II / US	Oral	Cytokinetics	
		Chronic obstructive pulmonary disease	P-II / US			
		Amyotrophic lateral sclerosis	P-II / US			
RPE cell program	Cell therapy (Retinal pigment epithelium cell)	Dry age-related macular degeneration, Stargardt's macular degeneration	P-II / US	Injection	In-house (Astellas Institute for Regenerative Medicine)	

Update from the previous announcement (Jan. 2017):

CK-2127107: Clinical development for amyotrophic lateral sclerosis has been initiated.

ASP0456 (linaclotide): LINZESS was launched in Japan in Mar. 2017 and the description for irritable bowel syndrome with constipation (IBS-C) has been removed.